PT  - JOURNAL ARTICLE
AU  - C. Perreault
AU  - M. Gyger
AU  - J. Boileau
AU  - Y. Bonny
AU  - S. Cousineau
AU  - M. Lacombe
AU  - R. Lavallee
AU  - E. Tawil
AU  - G. D'Angelo
TI  - Acute graft-versus-host disease after allogeneic bone marrow transplantation
DP  - 1983 Nov 01
TA  - Canadian Medical Association Journal
PG  - 969--974
VI  - 129
IP  - 9
4099  - http://www.cmaj.ca/content/129/9/969.short
4100  - http://www.cmaj.ca/content/129/9/969.full
SO  - CMAJ1983 Nov 01; 129
AB  - In 25 patients receiving allogeneic bone marrow transplants methotrexate was used to prevent acute graft-versus-host disease (GVHD). Acute GVHD, grades 2 to 4, developed in only 5 (20%) of the patients. The incidence of acute GVHD in other series of recipients of bone marrow transplants has ranged from 5% to 76%. A review of the literature suggests that this variation cannot be completely accounted for by age, type of disease treated by transplantation or type of GVHD prophylaxis. However, transfusion of allogeneic lymphocytes that have not been completely inactivated by irradiation (e.g., in platelet and granulocyte preparations) and inadequate isolation-decontamination procedures may increase the probability of GVHD following bone marrow transplantation.